Law360, New York (August 03, 2009, 4:38 PM ET) -- A federal judge has dismissed most of the claims brought by a group of employee benefit plans in a putative antitrust class action alleging that Biovail Corp. and GlaxoSmithKline PLC conspired to stifle the market for a generic version of antidepressant Wellbutrin XL.
Judge Mary A. McLaughlin of the U.S. District Court for the Eastern District of Pennsylvania on Friday granted the defendants' motion to dismiss claims under all but six state statutes, weeding out dozens of other claims brought under state antitrust and consumer protection...
Swath Of Claims Cut From Wellbutrin Antitrust Action
To view the full article, take a free trial now.
